New quinolinic derivatives as centrally active antioxidants.
A series of new 1,2-dihydro and 1,2,3,4-tetrahydroquinolines, synthesized from the corresponding propargylaniline intermediates, have been developed as antioxidants for the potential treatment of pathologies implicating central oxidative stress.
Dorey
G
G
Institut de Recherches Servier, Croissy-sur-Seine, France. gdorey@netgrs.com
Lockhart
B
B
Lestage
P
P
Casara
P
P
D000818:Animals; D000975:Antioxidants / Q000138:chemical synthesis* / Q000494:pharmacology*; D002460:Cell Line; D004583:Electrons; D005015:Ethoxyquin / Q000737:chemistry; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007546:Isoquinolines / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000138:chemical synthesis / Q000494:pharmacology; D016877:Oxidants / Q000633:toxicity; D018384:Oxidative Stress / Q000187:drug effects; D011805:Quinolinic Acids / Q000138:chemical synthesis* / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D014810:Vitamin E / Q000494:pharmacology; D020122:tert-Butylhydroperoxide / Q000037:antagonists & inhibitors / Q000633:toxicity
D000975:Antioxidants; D007546:Isoquinolines; D018696:Neuroprotective Agents; D016877:Oxidants; D011805:Quinolinic Acids; D014810:Vitamin E; D020122:tert-Butylhydroperoxide; D005015:Ethoxyquin